Impact of aberrant myeloid antigen expression on outcomes of patients with T-cell acute lymphoblastic leukemia

Mohamed Al-Zaabi, Murtadha Al-Khabori, Naglaa Fawaz, Sulayma Al-Lamki, Arwa Al-Riyami, Mohammed Al-Huneini, Muhanna Al-Muslahi, Salam Alkindi

Research output: Contribution to journalArticle

Abstract

Objectives: To evaluate the impact of myeloid antigen expression on complete remission (CR), event-free survival (EFS), and overall survival (OS) in patients with T-cell acute lymphoblastic leukemia (T-ALL) treated with intensive chemotherapy. Methods: We retrospectively reviewed consecutive patients diagnosed with T-ALL and treated in Sultan Qaboos University Hospital and Royal Hospital in Oman between 2004 and 2010. The diagnosis of T-ALL was established using French-American-British classification or World Health Organization criteria. Patients were considered having myeloid antigen expression if they expressed CD13, CD33, or both (My+ and My-). Results: Of the 39 patients, 38 were included in the study (25 patients with My- and median age of 18.4 years, 13 patients with My+ and median age of 22.0 years). Median follow-up was 12 months. Thirty-two out of the total cohort were eligible for response-rate assessment. Twenty-nine patients (90.6%) achieved CR with one or two courses of chemotherapy with similar CR rates between the two groups (p = 0.880). Twenty-five percent (5/20) of the patients with My- required two courses of induction, whereas 58.3% (7/12) of My+ required two courses of induction and the difference was statistically significant (p = 0.040). In the multivariable analysis; age, gender, initial white blood cell count, central nervous system disease, and myeloid antigen expression were not statistically significant predictors of CR. The EFS and OS were similar between the My+ and My- groups p = 0.180 and p = 0.440, respectively. Conclusions: Patients with T-ALL with myeloid antigen expression need more courses of induction; however, rates of CR, EFS, and OS are not different from those without myeloid antigen expression. Larger prospective studies are required to confirm these findings.

Original languageEnglish
Pages (from-to)189-193
Number of pages5
JournalOman Medical Journal
Volume32
Issue number3
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Antigens
Disease-Free Survival
Survival
Oman
Drug Therapy
Central Nervous System Diseases
Leukocyte Count
Prospective Studies

Keywords

  • Antigens
  • Immunophenotyping
  • Leukemia
  • Myeloid
  • Patient outcome assessment
  • T-lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Impact of aberrant myeloid antigen expression on outcomes of patients with T-cell acute lymphoblastic leukemia. / Al-Zaabi, Mohamed; Al-Khabori, Murtadha; Fawaz, Naglaa; Al-Lamki, Sulayma; Al-Riyami, Arwa; Al-Huneini, Mohammed; Al-Muslahi, Muhanna; Alkindi, Salam.

In: Oman Medical Journal, Vol. 32, No. 3, 01.05.2017, p. 189-193.

Research output: Contribution to journalArticle

@article{e98f73c33cc74888a9f310f9df95723e,
title = "Impact of aberrant myeloid antigen expression on outcomes of patients with T-cell acute lymphoblastic leukemia",
abstract = "Objectives: To evaluate the impact of myeloid antigen expression on complete remission (CR), event-free survival (EFS), and overall survival (OS) in patients with T-cell acute lymphoblastic leukemia (T-ALL) treated with intensive chemotherapy. Methods: We retrospectively reviewed consecutive patients diagnosed with T-ALL and treated in Sultan Qaboos University Hospital and Royal Hospital in Oman between 2004 and 2010. The diagnosis of T-ALL was established using French-American-British classification or World Health Organization criteria. Patients were considered having myeloid antigen expression if they expressed CD13, CD33, or both (My+ and My-). Results: Of the 39 patients, 38 were included in the study (25 patients with My- and median age of 18.4 years, 13 patients with My+ and median age of 22.0 years). Median follow-up was 12 months. Thirty-two out of the total cohort were eligible for response-rate assessment. Twenty-nine patients (90.6{\%}) achieved CR with one or two courses of chemotherapy with similar CR rates between the two groups (p = 0.880). Twenty-five percent (5/20) of the patients with My- required two courses of induction, whereas 58.3{\%} (7/12) of My+ required two courses of induction and the difference was statistically significant (p = 0.040). In the multivariable analysis; age, gender, initial white blood cell count, central nervous system disease, and myeloid antigen expression were not statistically significant predictors of CR. The EFS and OS were similar between the My+ and My- groups p = 0.180 and p = 0.440, respectively. Conclusions: Patients with T-ALL with myeloid antigen expression need more courses of induction; however, rates of CR, EFS, and OS are not different from those without myeloid antigen expression. Larger prospective studies are required to confirm these findings.",
keywords = "Antigens, Immunophenotyping, Leukemia, Myeloid, Patient outcome assessment, T-lymphocytes",
author = "Mohamed Al-Zaabi and Murtadha Al-Khabori and Naglaa Fawaz and Sulayma Al-Lamki and Arwa Al-Riyami and Mohammed Al-Huneini and Muhanna Al-Muslahi and Salam Alkindi",
year = "2017",
month = "5",
day = "1",
doi = "10.5001/omj.2017.36",
language = "English",
volume = "32",
pages = "189--193",
journal = "Oman Medical Journal",
issn = "1999-768X",
publisher = "Oman Medical Specialty Board",
number = "3",

}

TY - JOUR

T1 - Impact of aberrant myeloid antigen expression on outcomes of patients with T-cell acute lymphoblastic leukemia

AU - Al-Zaabi, Mohamed

AU - Al-Khabori, Murtadha

AU - Fawaz, Naglaa

AU - Al-Lamki, Sulayma

AU - Al-Riyami, Arwa

AU - Al-Huneini, Mohammed

AU - Al-Muslahi, Muhanna

AU - Alkindi, Salam

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Objectives: To evaluate the impact of myeloid antigen expression on complete remission (CR), event-free survival (EFS), and overall survival (OS) in patients with T-cell acute lymphoblastic leukemia (T-ALL) treated with intensive chemotherapy. Methods: We retrospectively reviewed consecutive patients diagnosed with T-ALL and treated in Sultan Qaboos University Hospital and Royal Hospital in Oman between 2004 and 2010. The diagnosis of T-ALL was established using French-American-British classification or World Health Organization criteria. Patients were considered having myeloid antigen expression if they expressed CD13, CD33, or both (My+ and My-). Results: Of the 39 patients, 38 were included in the study (25 patients with My- and median age of 18.4 years, 13 patients with My+ and median age of 22.0 years). Median follow-up was 12 months. Thirty-two out of the total cohort were eligible for response-rate assessment. Twenty-nine patients (90.6%) achieved CR with one or two courses of chemotherapy with similar CR rates between the two groups (p = 0.880). Twenty-five percent (5/20) of the patients with My- required two courses of induction, whereas 58.3% (7/12) of My+ required two courses of induction and the difference was statistically significant (p = 0.040). In the multivariable analysis; age, gender, initial white blood cell count, central nervous system disease, and myeloid antigen expression were not statistically significant predictors of CR. The EFS and OS were similar between the My+ and My- groups p = 0.180 and p = 0.440, respectively. Conclusions: Patients with T-ALL with myeloid antigen expression need more courses of induction; however, rates of CR, EFS, and OS are not different from those without myeloid antigen expression. Larger prospective studies are required to confirm these findings.

AB - Objectives: To evaluate the impact of myeloid antigen expression on complete remission (CR), event-free survival (EFS), and overall survival (OS) in patients with T-cell acute lymphoblastic leukemia (T-ALL) treated with intensive chemotherapy. Methods: We retrospectively reviewed consecutive patients diagnosed with T-ALL and treated in Sultan Qaboos University Hospital and Royal Hospital in Oman between 2004 and 2010. The diagnosis of T-ALL was established using French-American-British classification or World Health Organization criteria. Patients were considered having myeloid antigen expression if they expressed CD13, CD33, or both (My+ and My-). Results: Of the 39 patients, 38 were included in the study (25 patients with My- and median age of 18.4 years, 13 patients with My+ and median age of 22.0 years). Median follow-up was 12 months. Thirty-two out of the total cohort were eligible for response-rate assessment. Twenty-nine patients (90.6%) achieved CR with one or two courses of chemotherapy with similar CR rates between the two groups (p = 0.880). Twenty-five percent (5/20) of the patients with My- required two courses of induction, whereas 58.3% (7/12) of My+ required two courses of induction and the difference was statistically significant (p = 0.040). In the multivariable analysis; age, gender, initial white blood cell count, central nervous system disease, and myeloid antigen expression were not statistically significant predictors of CR. The EFS and OS were similar between the My+ and My- groups p = 0.180 and p = 0.440, respectively. Conclusions: Patients with T-ALL with myeloid antigen expression need more courses of induction; however, rates of CR, EFS, and OS are not different from those without myeloid antigen expression. Larger prospective studies are required to confirm these findings.

KW - Antigens

KW - Immunophenotyping

KW - Leukemia

KW - Myeloid

KW - Patient outcome assessment

KW - T-lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85020212995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020212995&partnerID=8YFLogxK

U2 - 10.5001/omj.2017.36

DO - 10.5001/omj.2017.36

M3 - Article

VL - 32

SP - 189

EP - 193

JO - Oman Medical Journal

JF - Oman Medical Journal

SN - 1999-768X

IS - 3

ER -